Foundation & Early Years
In 2014, our founder, Bill Vincent, laid the cornerstone for Genezen. By 2015, we had formed pivotal partnerships with Cincinnati Children’s Hospital and Indiana University, thus setting the stage for our journey into GMP-grade viral vector development and making us a vital player among viral vector manufacturing companies.
GMP Production
Genezen completes 25,000 ft2 expansion for lentiviral and retroviral GMP facility, complementing our process development, analytical development, and GMP cell banking. This expansion bolstered our commitment to excellence by allowing us to launch AAV contract manufacturing services.
Future Developments
Committed to technological and capacity advancements, Genezen is continuing construction on 75,000 total ft2 of state-of-the-art facilities. Simultaneously, we are conducting studies to assess the effectiveness of novel technologies, solidifying our position as leaders in viral vector CDMO services, including lentiviral vector production services and lentiviral gene therapy companies.
Our Mission
Our Mission: To drive the advancement of gene and cell therapies by providing science-driven development and manufacturing solutions.
We are a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral vector, and adeno-associated viral (AAV) vectors. We drive the advancement of gene and cell therapies by providing science-driven development and manufacturing solutions — a mission that unites our team as we work diligently to bring your gene or cell therapy successfully to clinic.
Explore careers at Genezen
Explore careers at Genezen
We are continuously in the pursuit of world-class talent. Do you have a passion for promoting scientific advancement? Are you hungry to grow alongside and help shape a fast-developing, science-led CDMO? You may be a perfect fit for Genezen.